The Medipattern Corporation

The Medipattern Corporation

June 09, 2010 08:30 ET

Medipattern Introduces New 3D Visualize™ Software for Vascular Ultrasound

-Navix Diagnostix to Preview Visualize™ at SVS/SVU Conference-

TORONTO, ONTARIO--(Marketwire - June 9, 2010) -

Attention: Business/Financial Editors

The Medipattern Corporation ("Medipattern") (TSX VENTURE:MKI), a pioneer in the development of medical software solutions that help improve imaging workflow and productivity, is pleased to announce Visualize™ for 2D and 3D review of ultrasound data. Visualize is a generic multimodality software created by Medipattern to support a variety of ultrasound applications including the planned Vascular iQ™ and will be used to consolidate all Medipattern offerings in one look and feel. 3D imagery from the Visualize:Vascular™ series will be included in the "case of the day" reviews displayed by Navix Diagnostix, Inc. at its booth at the 2010 Annual Vascular Meeting, sponsored jointly by the Society of Vascular Surgeons (SVS) and Society of Vascular Ultrasound (SVU), the largest vascular focused conference in North America.

"Visualize:Vascular is unique in that both the visualization of the vessel and its contents can potentially have broad application in vascular treatment options," commented Robert Kane, Senior Vice President of Business and Clinical Development for Navix Diagnostix. "We believe that all vascular clinicians including surgeons, radiologists, and cardiologists will benefit from using Visualize to understand the complete vessel."

Medipattern has worked closely with Navix Diagnostix to collect vascular data under Internal Review Board (IRB) monitoring in support of Medipattern's research and development efforts in the vascular market. The Visualize:Vascular software is Medipattern's first product developed for the vascular market, which represents 35 percent of the overall ultrasound imaging market.

"Through vessel segmentation and 3D rendering, Visualize shows clinicians a view of ultrasound imaging from a holistic perspective: for example the entire carotid artery from the common carotid artery through internal carotid artery, which is the pipeline to the brain, is reconstructed as a separate image that can be turned around and viewed from different angles. Prior to Visualize, ultrasound images of this area are displayed as separate slices through the neck that the clinician essentially uses to create a 3D picture in their mind. Visualize enables us to see the morphology of the artery alone and then goes beyond this to show the structure within the artery walls, thickening and blockages. Current practice is to measure flows and from this data to infer Stenosis. Blockage is inferred from lack of flow," comments Angela Rodriguez-Wong, MD, RVT from Navix Diagnostix. "Understanding the type and structure of the blockage will enable clinicians to better tailor the treatment to each patient's condition."

"Medipattern plans to show 3D visualization of carotid arteries from ultrasound images which is the first focus for our Visualize viewer series," states Jeff Collins, president and CEO of Medipattern. "We plan to gain feedback from all types of vascular clinicians: surgeons, radiologists and cardiologists; interventional and non-interventional; as well as sonographers at the conference. This information will guide us as we develop the product and submit it for FDA certification later this year. Once approved, we expect to offer the product under a software as a service or traditional license sales agreement."

Collins continues, "We thank our partners at Navix Diagnostix who have been instrumental in providing clinical guidance to us as we develop this new product. Navix Diagnostix is our anchor tenant planning to install Visualize in all of its vascular labs certified by the Intersocietal Commission for the Accreditation of Vascular Laboratories (ICAVL). Navix Diagnostix is committed to superb patient care through adherence to the finest standards and to leading edge technology speeding accurate care."

About The Medipattern Corporation:

Medipattern® is a pioneer in the development of medical software solutions that help improve imaging workflow and productivity. Our first-to-market, award-winning B-CAD® advances breast ultrasound computer aided detection (CAD) by streamlining workflow and organizing information into a comprehensive patient record. Medipattern uses its Cadenza™ CAD Technology to power the digital conversion in medical communications. B-CAD automatically creates fully digital standardized worksheets and reports that make every practice more efficient, productive and ultimately more effective. For more information, please visit the Company's website at:

B-CAD® and Medipattern® are a registered mark of The Medipattern Corporation.

Forward-looking statements

This document contains forward-looking statements relating to Medipattern's performance, operations, or business environment. These statements are based on what we believe are reasonable assumptions given currently available information and our understanding of Medipattern's current activities. We have tried, whenever possible, to identify these forward-looking statements using words such as "anticipates," "believes," "estimates," "expects," "plans," "intends," "potential", and similar expressions. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict or control. A number of factors could cause actual outcomes and results to differ materially from those expressed in forward-looking statements. These factors include but are not limited to those set forth in the Company's corporate filings, (posted at In addition, these forward-looking statements relate to the date on which they are made. The Company disclaims any intention or obligation to update or revise any forward-looking statements for any reason. Readers should not rely on forward-looking statements.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information